Allspring Global Investments Holdings LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Posted by on Apr 5th, 2023

Allspring Global Investments Holdings LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 3.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 39,666 shares of the biopharmaceutical company’s stock after selling 1,269 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $28,619,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MADDEN SECURITIES Corp purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Ronald Blue Trust Inc. increased its stake in shares of Regeneron Pharmaceuticals by 157.9% during the third quarter. Ronald Blue Trust Inc. now owns 49 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 30 shares during the period. Trifecta Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $42,000. MinichMacGregor Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $53,000. Finally, Carolinas Wealth Consulting LLC increased its stake in shares of Regeneron Pharmaceuticals by 39.3% during the third quarter. Carolinas Wealth Consulting LLC now owns 78 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.5 %

Regeneron Pharmaceuticals stock opened at $822.09 on Wednesday. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $835.00. The company has a market capitalization of $89.88 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 2.41 and a beta of 0.23. The stock has a 50-day moving average price of $767.53 and a 200 day moving average price of $743.00.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, topping analysts’ consensus estimates of $8.18 by $4.38. Regeneron Pharmaceuticals had a return on equity of 22.87% and a net margin of 35.64%. The firm had revenue of $3.41 billion during the quarter, compared to the consensus estimate of $3.11 billion. During the same quarter in the previous year, the company posted $23.72 earnings per share. The company’s revenue was down 31.1% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 34.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $925.00 to $940.00 in a research note on Thursday, March 30th. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, March 31st. EF Hutton Acquisition Co. I raised their price target on Regeneron Pharmaceuticals from $853.00 to $862.00 and gave the company a “buy” rating in a research note on Thursday, March 23rd. Robert W. Baird raised their price target on Regeneron Pharmaceuticals from $756.00 to $800.00 and gave the company a “neutral” rating in a research note on Friday, March 24th. Finally, BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,025.00 to $1,040.00 in a research report on Friday, March 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $840.57.

Insider Buying and Selling

In related news, CFO Robert E. Landry sold 183 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, March 27th. The stock was sold at an average price of $821.70, for a total transaction of $150,371.10. Following the completion of the sale, the chief financial officer now owns 32,929 shares of the company’s stock, valued at $27,057,759.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Robert E. Landry sold 183 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $821.70, for a total transaction of $150,371.10. Following the completion of the transaction, the chief financial officer now directly owns 32,929 shares in the company, valued at $27,057,759.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Christopher R. Fenimore sold 2,192 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $806.47, for a total value of $1,767,782.24. Following the transaction, the senior vice president now owns 18,409 shares of the company’s stock, valued at $14,846,306.23. The disclosure for this sale can be found here. Insiders sold 28,786 shares of company stock valued at $22,950,981 over the last quarter. 8.99% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.